About Menopause and Elestrin
Menopause and your patients
Your patients look to you for help in making the right decisions about their healthcare, including treating symptoms of menopause.
At this time in their lives, patients may have many concerns and questions, and almost as many choices. Some of the issues you can help them understand include1:
- The uncomfortable symptoms that some women experience with menopause
- That going through menopause is easier for some and harder for others
- The many options available to help women through this transition
Knowing they have someone who can provide guidance and support during this time can mean a great deal. Also important is knowing they have options right at their fingertips.
What is Elestrin?
Elestrin (estradiol gel) 0.06% is a treatment for moderate to severe vasomotor symptoms due to menopause.1
Elestrin (estradiol gel) 0.06% contains a form of exogenous estrogen sourced from plants.1
Exogenous estrogens are metabolized in the same manner as endogenous estrogens that occur naturally in the human body.1
Elestrin: Proven in a clinical trial to treat these menopausal symptoms
The safety and effectiveness of Elestrin was studied in a clinical trial of 484 postmenopausal women. That trial showed that Elestrin significantly reduced both the frequency and severity of hot flashes vs placebo at the end of the 12-week study.1
The safety and effectivness of Elstrin was studied in a clinical trial of 484 menopausal women. This study met the primary endpoint, showing a statistically significant reduction in hot flush frequency by Elestrin compared to placebo by the end of the 12-week study.1
Elestrin is a colorless, nonstaining gel that is applied once a day to the upper arm and shoulder using a metered-dose pump. There are two dosing options to choose from1:
- 1 pump provides a low dose of Elestrin (0.52 mg of estradiol)
- 2 pumps of Elestrin (1.04 mg of estradiol)
Patients should be started with the lowest effective dose of Elestrin, which is 1 pump per day (0.52 mg of estradiol).1
Subsequent dosing adjustments may be made based on individual patient response, which should be assessed periodically.1
References: 1. Elestrin [package insert]. Somerset, NJ: Meda Pharmaceuticals Inc.; 2014.